From June 9, 2022 to June 30, 2022, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 0 shares, representing 0% for CNY 0 million under the buyback announced on June 10, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.24 CNY | -0.41% | -0.97% | +0.66% |
27/05 | ZBD Pharma Gets China Approval for Gastric Acid Inhibiting Tablets | MT |
07/05 | China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.66% | 1.59B | |
+48.79% | 781B | |
+41.76% | 639B | |
+19.43% | 330B | |
+7.18% | 293B | |
+17.60% | 248B | |
-0.41% | 221B | |
+11.54% | 217B | |
+4.53% | 162B | |
-3.92% | 157B |
- Stock Market
- Equities
- 603567 Stock
- News Heilongjiang ZBD Pharmaceutical Co., Ltd.
- Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.